Table 6.
Association between antidiabetic regimens and glycemic control
| Antidiabetic regimens | A1C level (n, %)
|
P-valuea | |
|---|---|---|---|
| <8.0% | ≥8.0% | ||
| Biguanides | |||
| Yes | 52 (49.5) | 53 (50.5) | P=0.051b |
| No | 73 (63.5) | 42 (36.5) | |
| Sulfonylureas (in combination) | |||
| Yes | 72 (60.2) | 34 (32.1) | P=0.002b,* |
| No | 53 (46.5) | 61 (53.5) | |
| Meglitinides | |||
| Yes | 1 (100.0) | 0 (0.0) | P=1.000c |
| No | 124 (56.6) | 95 (43.4) | |
| TZDs | |||
| Yes | 0 (0.0) | 1 (100.0) | P=0.432c |
| No | 125 (57.1) | 94 (42.9) | |
| α-glucosidase inhibitors | |||
| Yes | 0 (0.0) | 3 (100.0) | P=0.079c |
| No | 125 (57.6) | 92 (42.4) | |
| GLP-1 agonists | |||
| Yes | 1 (100.0) | 0 (0.0) | P=1.000c |
| No | 124 (56.6) | 95 (43.4) | |
| DPP-4 inhibitors | |||
| Yes | 7 (58.3) | 5 (41.7) | P=1.000c |
| No | 118 (56.7) | 90 (43.3) | |
| Insulin (in combination) | |||
| Yes | 35 (39.8) | 53 (60.2) | P<0.001b,* |
| No | 90 (68.2) | 42 (31.8) | |
| Biguanides monotherapy | |||
| Yes | 19 (55.9) | 15 (44.1) | P=1.000b |
| No | 106 (57.0) | 80 (43.0) | |
| Sulfonylureas monotherapy | |||
| Yes | 40 (28.4) | 10 (21.6) | P<0.001b,* |
| No | 85 (50.0) | 85 (50.0) | |
| Insulin monotherapy | |||
| Yes | 27 (46.6) | 31 (53.4) | P=0.092b |
| No | 98 (60.5) | 64 (39.5) | |
| Biguanides and sulfonylureas | |||
| Yes | 25 (62.5) | 15 (37.5) | P=0.532b |
| No | 100 (55.6) | 80 (44.4) | |
| Biguanides and insulin | |||
| Yes | 6 (28.6) | 15 (71.4) | P=0.012b,* |
| No | 119 (59.8) | 80 (40.2) | |
| Biguanides, sulfonylureas, and DPP-4 inhibitors | |||
| Yes | 2 (40.0) | 3 (60.0) | P=0.654c |
| No | 123 (57.2) | 92 (42.8) | |
| Sulfonylureas and insulin | |||
| Yes | 1 (50.0) | 1 (50.0) | P=1.000c |
| No | 124 (56.9) | 94 (43.1) | |
| Biguanides, sulfonylureas, and insulin | |||
| Yes | 0 (0.0) | 2 (100.0) | P=0.185c |
| No | 125 (57.3) | 93 (42.7) | |
| Biguanides, sulfonylureas, DPP-4 inhibitors, and insulin | |||
| Yes | 1 (100.0) | 0 (0.0) | P=1.000c |
| No | 124 (56.6) | 95 (43.4) | |
| DPP-4 inhibitors and insulin | |||
| Yes | 1 (100.0) | 0 (0.0) | P=1.000c |
| No | 124 (56.6) | 95 (43.4) | |
| Biguanides and DPP-4 inhibitors | |||
| Yes | 1 (50.0) | 1 (50.0) | P=1.000c |
| No | 124 (56.9) | 94 (43.1) | |
| Biguanides, sulfonylureas, and α-glucosidase inhibitors | |||
| Yes | 0 (0.0) | 2 (100.0) | P=0.185c |
| No | 125 (57.3) | 93 (42.7) | |
| Sulfonylureas and meglitinides | |||
| Yes | 2 (100.0) | 0 (0.0) | P=0.507c |
| No | 123 (56.4) | 95 (43.6) | |
| Sulfonylureas and TZDs | |||
| Yes | 1 (50.0) | 1 (50.0) | P=1.000c |
| No | 124 (56.9) | 94 (43.1) | |
| Sulfonylureas and DPP-4 inhibitors | |||
| Yes | 3 (57.1) | 3 (42.9) | P=1.000c |
| No | 121 (56.8) | 92 (43.2) | |
Notes:
a
Degree of freedom =1;
b
Pearson chi-square test with continuity correction;
c
Fisher exact test;
*
statistically significant (P<0.05).
Abbreviations: A1C, glycated hemoglobin; GLP-1 agonists, glucose-like peptide-1 agonists; DPP-4 inhibitors, dipeptidyl peptidase-4 inhibitors; TZDs, thiazolidinediones.